Pfizer (PFE) PT Lowered to $36 at JPMorgan

Pfizer (PFE) PT Lowered to $39 at Wolfe Research

Wolfe Research analyst Tim Anderson lowered the price target on Pfizer (NYSE: PFE) to $39.00 (from $41.00) while maintaining a Peerperform rating.

The analyst comments "We lower our peak estimate for Ibrance in 2027 (the year before patent loss) from $10.1B to $8.1B, with the decrement... More

UPDATE: Pfizer (PFE) PT Lowered to $37 at UBS

(Updated - June 1, 2020 7:32 AM EDT)

(updating comment)

UBS analyst Navin Jacob lowered its price target on Pfizer (NYSE: PFE) to $37.00 (from $39.00) while maintaining a Neutral rating.

The analyst comments "Consensus appears to model ~$3B for Ibrance's adjuvant breast cancer indication (2020/2026 = $5.5B / $8.2B). PFE after-market on Friday fell 7%, in-line... More

Pfizer (PFE) PT Lowered to $37 at Citi

(updating comment)

Citi analyst Andrew Baum lowered the price target on Pfizer (NYSE: PFE) to $37.00 (from $41.00) while maintaining a Neutral rating.

The analyst comments "We have struggled for many years to have conviction on PFE given the burden of competitive pressures (generics,... More

Pfizer (PFE) Shares Plunge Post-Market, Down 8% After Phase 3 PALLAS Trial of IBRANCE in Breast Cancer Fails

Pfizer (NYSE: PFE) Shares Plunge Post-Market, Down 8% After Phase 3 PALLAS Trial of IBRANCE in Breast Cancer Fails

Pfizer (PFE) Phase 3 PALLAS Trial of IBRANCE Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer Unlikely to Show Statistically Significant Improvement

(Updated - May 29, 2020 4:18 PM EDT)

As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee (DMC) of the collaborative Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS). Patients currently receiving palbociclib in the study will be advised about next steps... More

Pfizer (PFE), Astellas Announce Final PROSPER Results Show XTANDI Significantly Extends OS in Men with Non-Metastatic Castration-Resistant Prostate Cancer

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") have announced final results from the overall survival (OS) analysis of the Phase 3 PROSPER trial, which evaluated XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC). In the trial, XTANDI... More